---
title: "Glaukos completes enrollment in 510(k) pivotal study of PRESERFLO MicroShunt for advanced glaucoma patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293920684.md"
description: "Glaukos Corporation has completed patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt, a device designed to treat advanced primary open-angle glaucoma. The trial aims to demonstrate the device's ability to lower eye pressure without increasing reliance on medications. Results are expected after a 12-month postoperative follow-up and will support an FDA marketing submission. The MicroShunt is already commercially available in markets such as Canada and Australia."
datetime: "2026-07-27T11:02:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293920684.md)
  - [en](https://longbridge.com/en/news/293920684.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293920684.md)
generator: "portal-rs"
---

# Glaukos completes enrollment in 510(k) pivotal study of PRESERFLO MicroShunt for advanced glaucoma patients

-   Glaukos completed patient enrollment in a U.S. 510(k) pivotal study for the PRESERFLO MicroShunt in advanced primary open-angle glaucoma. \* Results have not been presented; the study will read out following 12-month postoperative follow-up. \* The trial is designed to show the device can lower eye pressure without increasing reliance on glaucoma medications. \* Data are intended to support a future FDA marketing submission, positioning the MicroShunt as an alternative to conventional filtration surgery. \* The device is already sold in several markets including Canada and Australia, providing an early commercial base ahead of a U.S. filing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607270700BIZWIRE\_USPR\_\_\_\_\_20260727\_BW338754) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [GKOS.US](https://longbridge.com/en/quote/GKOS.US.md)

## Related News & Research

- [Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today](https://longbridge.com/en/news/296936383.md)
- [357,148 Shares in Glaukos Corporation $GKOS Purchased by Bank of New York Mellon Corp](https://longbridge.com/en/news/297278793.md)
- [Glaukos (GKOS), Why Is The Story Getting Harder To Ignore?](https://longbridge.com/en/news/296739885.md)
- [Glaukos director Gilbert H. Kliman disposes of 2,500 common shares for $475,000](https://longbridge.com/en/news/296547975.md)
- [Glaukos publishes investor presentation highlighting interventional glaucoma, keratoconus pipeline programs](https://longbridge.com/en/news/294684110.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**